Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 10:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: MF-only Clear all
Recruiting Phase 1 Interventional

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

NCT06834282
View directory record Official record
Conditions
AML, Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
CER-1236, Cyclophosphamide, Fludarabine, Mesna
Drug
Lead sponsor
CERo Therapeutics Holdings, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Sacramento, California • Denver, Colorado • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 4, 2026, 10:18 AM EDT
Completed Phase 2 Interventional Results available

Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

NCT01445769
View directory record Official record
Conditions
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
21
States / cities
Highland, California • La Jolla, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 4, 2026, 10:18 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

NCT03227471
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
IVA, TEZ/IVA, VX-445, Matched Placebo, TEZ, VX-561
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
26
States / cities
Tucson, Arizona • Little Rock, Arkansas • Madera, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 4, 2026, 10:18 AM EDT
Recruiting Phase 2 Interventional

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

NCT04858256
View directory record Official record
Conditions
T-Cell Neoplasm, Lymphoproliferative Disorders
Interventions
Pacritinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
6
States / cities
Duarte, California • Tampa, Florida • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 4, 2026, 10:18 AM EDT
Terminated Not applicable Interventional Results available

Multifocal Visual Performance Study

NCT03757039
View directory record Official record
Conditions
Presbyopia
Interventions
Multifocal soft contact lenses, Progressive addition lens spectacles
Device · Other
Lead sponsor
Alcon Research
Industry
Eligibility
38 Years to 58 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Sep 4, 2026, 10:18 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Classroom Break, Cognition, and Fitness in Elementary School Children

NCT06258941
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MF-HIIT, HIIT-only, MF-only, Sedentary activity
Behavioral
Lead sponsor
Purdue University
Other
Eligibility
8 Years to 12 Years
Enrollment
352 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Royal Center, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 4, 2026, 10:18 AM EDT
Recruiting Phase 1 Interventional

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

NCT06150157
View directory record Official record
Conditions
Neoplasms
Interventions
JNJ-88549968, Ruxolitinib, Momelotinib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
Duarte, California • Aurora, Colorado • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 4, 2026, 10:18 AM EDT
Completed Phase 2 Interventional Results available

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

NCT02098161
View directory record Official record
Conditions
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Laboratory Biomarker Analysis, Questionnaire Administration, Smac Mimetic LCL161
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Sep 4, 2026, 10:18 AM EDT
Terminated Phase 2 Interventional Results available

AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis

NCT03718143
View directory record Official record
Conditions
Myelofibroses, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Combination AZD1775 with AraC, AZD1775 only
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Sep 4, 2026, 10:18 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Phase I Study to Evaluate the Safety and Efficacy of MF101 as Well as the Pharmacokinetics of Its Key Active Components

NCT00453297
View directory record Official record
Conditions
Healthy
Interventions
MF101
Drug
Lead sponsor
Bionovo
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 28, 2008 · Synced Sep 4, 2026, 10:18 AM EDT
Active, not recruiting Phase 1 Interventional

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

NCT04041050
View directory record Official record
Conditions
Myeloproliferative Neoplasm
Interventions
Navitoclax, Ruxolitinib, Celecoxib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
12
States / cities
Duarte, California • Fullerton, California • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 4, 2026, 10:18 AM EDT
Completed Phase 3 Interventional Results available

FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

NCT02448381
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma
Interventions
SGX301 (synthetic hypericin), Placebo
Drug
Lead sponsor
Soligenix
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Sep 4, 2026, 10:18 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Moderators and Mediators of Perceptual Learning

NCT05894967
View directory record Official record
Conditions
Cognitive Change
Interventions
C1 - Standard Perceptual Learning (SPL), C2 - Long Training (LT), C3 - Short Staircases (SS), C4 - Mixed Difficulty (MD), C5 - Noise Training (NT), C6 - Training with Flankers (TWF), C7 - Parafoveal Training (PT), C8 - Stimulus Variety (SV), C8a - Complex Features (CF), C9 - Exogenous Attention Training (ExAT), C10 - Endogenous Attention Training (EnAT), C11 - Multisensory Facilitation (MF), No Contact Control
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 85 Years
Enrollment
1,140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
3
States / cities
Riverside, California • Boston, Massachusetts • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 4, 2026, 10:18 AM EDT
Completed Phase 2 Interventional Results available

Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)

NCT02267278
View directory record Official record
Conditions
Myeloproliferative Diseases
Interventions
Ruxolitinib, Pracinostat, Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 4, 2026, 10:18 AM EDT
Withdrawn Phase 2 Interventional

PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

NCT04054245
View directory record Official record
Conditions
Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
Interventions
LOXL2 Inhibitor PAT-1251, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Sep 4, 2026, 10:18 AM EDT
Suspended Early Phase 1 Interventional

Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)

NCT06235281
View directory record Official record
Conditions
Mycosis Fungoides
Interventions
Mogamulizumab-Kpkc, Phototherapy
Drug · Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 4, 2026, 10:18 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

NCT04562870
View directory record Official record
Conditions
Myelofibrosis
Interventions
Selinexor, Physician's Choice Treatment
Drug · Other
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Pasadena, California • Aurora, Colorado • Niles, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 4, 2026, 10:18 AM EDT